Daily FNArena News

Transurban performed to expectations in its FY14 results and brokers expect the outlook will remain strong while interest rates are favourable.

Cochlear surprised the market and brokers with a better performance in the second half, but concerns abound around market share and growth in the company’s core business.

A summary of the previous session’s corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

Are you feeling lukcy? Peter Switzer of the Switzer Super Report discusses investment during a correction.

A wrap of the day’s activity on the Australian stock market.

Will KKR pull its bid for Treasury Wine following due dilligence? Or could another bidder emerge?

Michael Gable of Fairmont Equities reports the technicals are looking better for beaten-down Atlas Iron.

July witnessed a surge in uranium trading volumes as buyers took advantage of lower prices, although oversupply is keeping pricing steady.

While some brokers have brushed aside recent sales weakness as temporary, others are not so sure ResMed’s growth rates will rebound substantially.

As fears of an impending Fed rate rise build, Kathleen Brooks of FOREX.com argues why this should not necessarily be negative for Wall Street.